OMASPECT – Sponsored by Hoffmann-La Roche

Completed Study | Duration: 96 weeks

OMASPECT was a multicenter, open-label extension study for the treatment of age-related macular degeneration (AMD). This study evaluated the long-term safety and tolerability of intravitreal Lampalizumab for treatment of geographic atrophy (GA) secondary to AMD. Lampalizumab is a monoclonal antibody directed against complement factor D, which plays a role in the complement-mediated destruction of retinal layers as seen in GA. This study was for patients rolled over from the original SPECTRI trial who had completed their Week 96 visit.

Return to Age-Related Macular Degeneration


Loading ...

Ophthalmologist Website Design | Accessibility Policy
Washington DC OMASPECT Study | AMD Treatment in Maryland | Virginia OMASPECT Study